Every day, someone calls the bottom in pharmaceutical stocks. I keep seeing the headline "Is it time to buy big pharma?" and then I hear some manager, who obviously genuinely believes that the bottom is here, drone on about how


(MRK) - Get Report

right, or


(LLY) - Get Report

right or


(PFE) - Get Report


Having run Syntex down almost to zero a decade ago, and having watched


(BMY) - Get Report

and then



chronically underperform for years, I have to wonder: What the heck's so appealing now? Is it price? Do people really think these stocks are bought on price? If they do, I have to tell you that the price is


right. There's nothing particularly appealing about the yield of Merck, say, that isn't appealing about the yield of Bristol-Myers, and Bristol-Myers hasn't done anything for years.

Is it the buybacks? Is that what inspires people? If it is the buybacks, let me ask you a question: Have these buybacks, which are like


(KO) - Get Report



(CSCO) - Get Report

in their repetitive nature, been responsible for


point on the upside? Have they done anything good for you?

Is it the pipeline? Maybe, except all I see are me-too cholesterol drugs that are very similar and competitive in nature -- competitive meaning that the prices can't stay high.

Is it the distribution method? Do you really think that Merck is going to be unscathed because its Medco unit distributed statistically more Vioxx than Celebrex, even though someone at Medco should have known how many heart attacks the drug was causing?

Is it the political climate? Oh please, New Jersey went for Kerry. Do you really think that the president wants to help this industry, which, incredibly, is populated almost exclusively in blue states? You have to be kidding me.

Is it the possibility for tort reform? Yeah, I will believe it when I see it. It wasn't just the Democrats who stopped tort reform before. There were Republicans -- Sen. Richard Shelby (R., Ala.) -- who betrayed the president. There are too many lawyers in Congress and not enough businesspeople for us to hope, realistically, that something can be accomplished in time to save these companies from the current rounds of litigation.

I don't like calling bottoms; I don't like being the butcher block to the falling knife. I particularly don't like to call bottoms when I see no catalyst out there other than sentiment: "This must be the bottom because it is really bad."

Oh, please. Secular negative trends don't lead to investing bottoms. Don't believe me? Look at

radio stocks. Look at cable stocks. Try as I might to defend the former, the


(SIRI) - Get Report

gambit's too powerful. The latter? I still think I am right, but only with


(CMCSA) - Get Report

, the "good" operator.

So, let the chattering classes chatter on about the bottom in the drug stocks.

Me? I'll keep looking elsewhere.

At the time of publication, Cramer was long Comcast.

James J. Cramer is a director and co-founder of TheStreet.com. He contributes daily market commentary for TheStreet.com's sites and serves as an adviser to the company's CEO. Outside contributing columnists for TheStreet.com and RealMoney.com, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made.

To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for

Action Alerts PLUS. While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column to

jjcletters@thestreet.com. Listen to Cramer's RealMoney Radio show on your computer; just click



here to buy Cramer's latest book, "You Got Screwed!" Click

here to order Cramer's autobiography, "Confessions of a Street Addict."